Theralase Technologies Inc. (CVE:TLT – Get Free Report)’s stock price traded up 10.2% during trading on Tuesday . The stock traded as high as C$0.28 and last traded at C$0.27. 223,000 shares were traded during mid-day trading, an increase of 115% from the average session volume of 103,522 shares. The stock had previously closed at C$0.25.
Theralase Technologies Stock Performance
The company’s 50-day simple moving average is C$0.27 and its 200 day simple moving average is C$0.23. The stock has a market cap of C$67.52 million, a P/E ratio of -13.75 and a beta of 1.36. The company has a current ratio of 1.21, a quick ratio of 3.40 and a debt-to-equity ratio of 20.58.
About Theralase Technologies
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Featured Articles
- Five stocks we like better than Theralase Technologies
- 5 Top Rated Dividend Stocks to Consider
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Where Do I Find 52-Week Highs and Lows?
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Stock Analyst Ratings and Canadian Analyst Ratings
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
